Uruguay's Cannabis Culture: From Underground Roots to State Control

August 15, 2026

Photo by Nikolai Kolosov via Pexels.

Introduction

Uruguay's cannabis law was never meant to be a global blueprint. It was a local fix for a local problem. For decades, the country had lived with a strange contradiction: possession for personal use was technically tolerated, but there was no legal way to actually get the plant. People grew it in backyards, traded cuttings among friends, and relied on informal networks because the alternative was buying from the illegal supply chain that the law never fully addressed. José Mujica, the former guerrilla who became president, saw this gap as a security issue more than a moral one. His 2013 law didn't open a free market. It built three narrow channels: home growing, member clubs, and pharmacy sales, all tracked by a single government registry. More than ten years later, that system is still in place. It has moved over nine tons of cannabis in a single year, pushed out the cheap smuggled weed that once dominated the streets, and is now considering whether to let tourists in. But it also remains deliberately modest, and its successes come with clear limits.

Before the Law: Cannabis Culture Underground

Photo by Nikolai Kolosov via Pexels.

Long before Uruguay became the first country to fully nationalize its cannabis supply chain, ordinary Uruguayans were already smoking, growing, and quietly trading weed under a legal arrangement that nobody could quite explain in plain terms. A 1974 decree, issued under military rule, drew a line between possession for personal use and possession for sale, leaving the former in a kind of tolerated limbo. Judges had discretion to look the other way if the quantity seemed personal rather than commercial, but there was no defined threshold, no registry, no protection written into statute. You could be left alone by a sympathetic prosecutor, or you could be the one whose case became an example. That ambiguity sat unresolved for almost forty years.

What made the gray zone workable, in practice, was the total absence of a legal supply. Possession might be tolerated; growing, buying, or selling to get there was not. So people grew for themselves, in back patios and spare rooms, and they leaned on friends and neighbors rather than dealers when they needed to restock. Seeds and clones moved through small, trusted circles -- a cutting from a neighbor's plant, a handful of seeds saved from a good harvest and passed along at a family barbecue. It was closer to a village seed-swap than anything resembling a drug market, and that informality became its own kind of protection: fewer transactions meant fewer chances to get caught in the part of the law that wasn't forgiving.

José Mujica, who became president in 2010, brought a very particular history to the question. As a former Tupamaro guerrilla who spent over a decade in prison under the dictatorship, he wasn't inclined toward moral arguments about personal freedom or wellness -- his case for legalization, pushed through in 2013, was framed almost entirely as a security policy. The target wasn't the smoker; it was the trafficker profiting from the gap between tolerated use and criminalized supply. Mujica argued repeatedly that prohibition had simply handed a captive market to organized crime, and that the state could starve that market by controlling it directly.

That argument landed at a moment when several Latin American governments were airing open fatigue with the drug war's costs, from Mexico's cartel violence to Colombia's decades of conflict. Uruguay didn't just join that conversation -- it outpaced it, becoming the only country in the hemisphere to have the state itself regulate cultivation, pricing, and pharmacy sales, rather than simply decriminalizing possession as many neighbors were beginning to consider.

Law 19.172: Building a State-Run Market

Photo by Tima Miroshnichenko via Pexels.

José Mujica put his signature on Law 19.172 on December 20, 2013, and the text that emerged was narrower and more bureaucratic than the global headlines suggested at the time. Uruguay wasn't opening a marijuana marketplace so much as building three separate, tightly monitored pipelines for the same plant. A resident could register to grow up to six plants at home. A group of 15 to 45 people could form a membership club (a club cannábico) and cultivate collectively, capped at 99 plants per club. Or a resident could register with the state to buy a limited monthly allotment directly from a pharmacy counter. Three routes, one national registry behind all of them, and nothing resembling a walk-in dispensary anywhere in the model.

Running that registry fell to a new agency, the Instituto de Regulación y Control del Cannabis, or IRCCA, housed within the presidency's orbit rather than left to municipalities or the health ministry alone. IRCCA licenses the growers who supply pharmacies, sets potency and pesticide standards, tracks how many grams each registered buyer has purchased that month, and audits club cultivation sites. It's a small agency by the standards of, say, a U.S. state cannabis control board, but it was designed to be the single choke point through which every legal gram in the country passes on paper. That centralization was the point: Uruguay wanted traceability from seed to counter, not a patchwork of private licenses issued by competing bureaus.

What the law didn't deliver, at least not quickly, was the piece most outsiders assumed would launch first. Pharmacy sales, the version of legalization that actually put product on a shelf for ordinary registered buyers, didn't start until July 19, 2017 — nearly four years after Mujica's signature. In the interim, home growers and club members had legal cover, but anyone who'd registered hoping to simply buy from a pharmacy had to wait through IRCCA's licensing of cultivators, seed-to-sale software rollout, banking hesitancy from institutions wary of federal-level scrutiny in correspondent countries, and repeated delays in getting the first two commercial growers, Simbiosys and Iccorp, into production at scale.

None of this was accidental minimalism. Uruguay's negotiators wrote the law explicitly to avoid an American-style commercial cannabis industry — no branded storefronts, no advertising, no private dispensary chains competing on flower quality or price. Pharmacies dispense a state-approved, unbranded product at a fixed price, the same way they'd hand over a regulated pharmaceutical, which was exactly the comparison the law's architects wanted people to draw.

Who's Buying, and What They're Buying

Photo by RDNE Stock project via Pexels.

Walk into one of Uruguay's 40 authorized pharmacies and you're looking at roughly 75,000 registered adult consumers who've opted for the state-sanctioned route rather than growing their own or joining a club. That's the largest of the three legal channels Uruguay set up back in 2013, and it's the one most visible to outsiders -- the pharmacy counter, the ID scan, the monthly purchase cap. But it's worth remembering this is only one leg of a three-legged system. Another 15,796 people belong to 460 registered cannabis clubs scattered around the country, cooperative growing operations capped by law at a set number of plants and members. Close to 12,000 more skip both options entirely and grow at home under their own registration, tending a handful of plants in a spare room or a backyard shed. Add it up and you get a population of well over 100,000 Uruguayans who've chosen to move their consumption into the regulated system rather than stay in the gray market that dominated for decades before 2013.

What they're actually buying is narrower than the strain names might suggest. The Instituto de Regulación y Control del Cannabis (IRCCA) approves exactly four varieties for pharmacy sale: Alfa, Beta, Gamma, and Epsilon. Alfa and Beta were the original workhorses, modest-potency flower meant to undercut illicit prices while keeping THC content low enough to ease regulators' nerves. Gamma came later as a middle option. Epsilon is the outlier -- THC content up to 20%, closer to what consumers in Colorado or Barcelona's cannabis clubs would recognize as standard commercial-grade flower rather than a government-issue product.

The purchase data from December 2025 makes the consumer preference impossible to ignore: pharmacies dispensed nearly 495,000 grams that month, and about 75% of it was Epsilon. Uruguayans aren't buying the mild stuff out of loyalty to the original public-health framing of the law -- they're buying the strongest legal option available, in bulk, the same way consumers anywhere gravitate toward potency once price and access stop being the limiting factors.

IRCCA has responded to rising demand and presumably rising cultivation costs by raising prices in stages -- an increase in August 2025, another set for February 2026, and a further adjustment planned from August 1, 2026, applied across all four strains. It's a deliberate, telegraphed approach rather than a sudden shock, letting registered buyers and club members see the schedule coming rather than face a surprise at the register.

Record Harvests: 2025's Sales Numbers

Uruguay's legal cannabis production grew steadily from 2023 to 2025, rising from 2,767 kg to 4,658 kg—a nearly 70% increase over just three years.

Pharmacy ledgers across Montevideo tell a clearer story than any government press release could. In 2025, Uruguay moved more than 9 tons of legal cannabis through its state-regulated adult-use system, the highest annual volume since sales began back in 2017. That's not a modest uptick -- it's the kind of number that suggests a market finally settling into its stride rather than testing the waters.

Break it down and the growth looks even more deliberate. Pharmacy purchases -- the actual product moving over the counter to registered users -- hit 4,290 kilos in 2025. Compare that to 3,207 kilos in 2024 and 3,254 in 2023, and you're looking at a jump of more than a thousand kilos in a single year, after two years that were basically flat against each other. Something shifted in 2025, whether that's more pharmacies carrying product, more registered buyers actually showing up, or existing users simply buying more per visit.

Production numbers back up the demand side of that equation. The four government-approved varieties -- the strains cultivated under license for the legal market -- totaled 4,658 kilos of output in 2025, again outpacing 2024's 3,374 kilos and 2023's 2,767. Growers under contract with the Instituto de Regulación y Control del Cannabis (IRCCA) had to scale up to keep pharmacy shelves stocked, and the fact that production climbed in step with sales rather than lagging behind it points to a supply chain that's no longer improvising.

What makes this data set worth paying attention to isn't just the raw tonnage -- it's the trajectory. A program that grows every single year for three straight years, more than a decade after José Mujica signed the original law in 2013, isn't a novelty program limping along on symbolic value. It's a functioning agricultural and retail sector with repeat customers. Uruguay's model was never built for scale in the way Canada's or California's commercial markets were -- pharmacy caps, registration limits, and a state monopoly on distribution keep it deliberately small. But within those self-imposed constraints, 2025's numbers show a system that finally found its footing after years of pharmacies dropping out, supply shortages, and banking headaches that plagued the program's first several years.

Did It Actually Kill the Black Market?

Photo by Kampus Production via Pexels.

The numbers, at least, are not in dispute. Uruguay's National Drug Board (Junta Nacional de Drogas) has now run two formal evaluations of the 2013 law, and the second one gives the clearest picture yet of what a decade of legal weed actually did to the illegal trade it was supposed to replace. Prensa paraguaya, once the dominant product on the street, has all but collapsed as a category. In 2014, that low-grade, often seed-and-stem-heavy pressed marijuana smuggled mostly from Paraguay accounted for 58.2% of what Uruguayan consumers were smoking. By 2024, that figure had fallen to 6.7%. That's not a gradual decline, that's a product category getting pushed to the margins of a market that no longer wants it.

Meanwhile the regulated system, pharmacy sales, home grows, and the roughly 270 cannabis clubs registered with the state, now formally accounts for 46.7% of how consumers say they get their cannabis. That's the headline figure the Board is using to argue the law is doing what it was designed to do: pull people out of criminal supply chains and into a system where potency, contaminants, and sourcing are at least nominally tracked. On the health side, the same evaluation reported no significant negative impacts attributable to regulation, no spike in problematic use, no measurable rise in cannabis-related emergency visits tied to the legal supply itself, which is the kind of finding public health officials elsewhere have been waiting years for.

But 46.7% replacing 58.2% of prensa doesn't add up to full displacement of the informal market, it just means the informal market changed shape. Close to 30% of consumers are still getting their cannabis through gray-market channels, sourcing outside pharmacies and outside the club system entirely, whether that's a grower friend selling off surplus, small unregistered plots, or product that never touches the state's tracking. It's not the old black market of smuggled bricks anymore. It's something messier and more informal, adjacent to the legal system rather than opposed to it.

Daniel Radio, the Board's secretary general, has offered a fairly candid explanation for why that gray zone persists: potency. Pharmacy cannabis in Uruguay has historically been capped at modest THC levels, and demand has kept climbing for stronger flower than the regulated channel is set up to deliver. Some consumers aren't avoiding the legal market out of distrust, they're going around it because it doesn't yet sell what they want.

Tourists, Exports, and What Comes Next

Photo by Andy Li via Unsplash.

Walk into a farmacia in Montevideo hoping to buy weed as a foreign visitor, and you'll leave empty-handed. That's the piece of Uruguay's system that surprises people most, especially those arriving with the impression that legal cannabis works the same everywhere. It doesn't. Purchases through the registered system -- whether at pharmacies, through the club model, or via home grow registration -- are restricted to citizens and legal residents who are at least 18 and enrolled in IRCCA's registry. There's no dispensary storefront equivalent to what you'd find in Denver or Toronto where a passport and a credit card get the job done. Tourists are, technically, left out entirely, which is a strange position for the country that started this whole global experiment back in 2013.

That gap hasn't gone unnoticed inside the government. President Yamandu Orsi, who took office in March 2025, has been more vocal than his immediate predecessors about treating cannabis policy as something still under construction rather than a finished project. His administration hasn't announced a specific tourist-sales plan, but officials have made clear the current restriction isn't treated as permanent doctrine -- more like an unresolved design question left over from a law written when tourism revenue wasn't the point.

Martin Rodriguez, IRCCA's executive director, has been the clearest voice on this. He's confirmed publicly that the agency is actively studying mechanisms that would let visitors access cannabis legally, without abandoning the registry-based control that's defined the Uruguayan approach since the start. Nobody's pretending this is simple -- building a tourist-access system means answering questions about quantity limits, verification, and how to keep a system built around identified, tracked buyers from becoming an open retail market. But the fact that IRCCA is running this analysis at all signals the conversation has moved from whether to how.

Exports are the part of the industry already working at scale. Uruguay permits licensed medicinal cannabis and CBD shipments under joint Ministry of Public Health and IRCCA authorization, and product has been moving to Germany, Israel, Brazil, and Portugal -- markets with their own established medical cannabis import frameworks. That trade line is likely to dominate discussion at the 13th ExpoCannabis Uruguay in Montevideo in 2026, the first full conference cycle since José Mujica's death in May 2025. Expect the mood there to carry some weight beyond the usual trade-show energy: an industry reckoning with the loss of the man who made the original law possible, while trying to figure out how to grow past what he built.

Conclusion

A decade of data shows Uruguay's experiment is working in several important ways. The legal channels now supply almost half of all consumption. The old Paraguayan brick weed, which made up nearly 60 percent of the market in 2014, is down to less than 7 percent. Pharmacy sales keep climbing, and the registry has over 100,000 users. Public health indicators haven't shown the spikes that critics feared.

Still, the system has not fully replaced the informal market. About 30 percent of consumers still get their cannabis outside the regulated channels, often because they want stronger flower than the pharmacy offers. The government has noticed. They approved a higher potency strain, Epsilon, and it now accounts for three quarters of all pharmacy purchases. Tourists remain locked out, though the new administration is actively studying how to change that without breaking the registry model.

Mujica died in May 2025, and the industry is now figuring out what comes next. Exports to Europe and Israel are already moving, and the upcoming ExpoCannabis conference will likely focus on that side of the business. The original vision was never about scale or branding. It was about control. Whether Uruguay stays content with that modest framework or decides to expand it will shape whether this remains a successful small scale experiment or becomes something else entirely.